Group One Trading, L.P. Myovant Sciences Ltd. Transaction History

Group One Trading, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$7.78 - $14.69 $189,443 - $357,701	-24,350 Reduced 70.23%	10,323 $128,000
Q1 2022 May 12, 2022	BUY	$11.38 - $16.4 $132,292 - $190,649	11,625 Added 50.44%	34,673 $462,000
Q4 2021 Feb 11, 2022	BUY	$14.31 - $23.87 $179,676 - $299,711	12,556 Added 119.67%	23,048 $359,000
Q3 2021 Nov 12, 2021	SELL	$18.94 - $26.99 $227,071 - $323,583	-11,989 Reduced 53.33%	10,492 $235,000
Q2 2021 Aug 10, 2021	SELL	$17.07 - $24.56 $83,557 - $120,221	-4,895 Reduced 17.88%	22,481 $512,000
Q1 2021 May 12, 2021	BUY	$20.46 - $25.18 $560,112 - $689,327	27,376 New	27,376 $563,000
Q4 2020 Feb 10, 2021	SELL	$13.8 - $27.62 $15,428 - $30,879	-1,118 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$14.05 - $22.6 $176,720 - $284,262	-12,578 Reduced 91.84%	1,118 $16,000
Q2 2020 Aug 13, 2020	SELL	$7.34 - $20.84 $54,719 - $155,362	-7,455 Reduced 35.25%	13,696 $282,000
Q1 2020 May 13, 2020	SELL	$6.55 - $14.76 $146,051 - $329,118	-22,298 Reduced 51.32%	21,151 $160,000
Q4 2019 Feb 10, 2020	BUY	$4.2 - $19.21 $182,485 - $834,655	43,449 New	43,449 $674,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.